Morgan Stanley’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-197,652
| Closed | -$4.01M | – | 7937 |
|
|
2022
Q4 | $4.01M | Buy |
197,652
+190,441
| +2,641% | +$2.92M | ﹤0.01% | 3941 |
|
|
2022
Q3 | $77K | Sell |
7,211
-1,546
| -18% | -$17.5K | ﹤0.01% | 6212 |
|
|
2022
Q2 | $105K | Sell |
8,757
-17,918
| -67% | -$289K | ﹤0.01% | 6250 |
|
|
2022
Q1 | $571K | Sell |
26,675
-7,661
| -22% | -$203K | ﹤0.01% | 5330 |
|
|
2021
Q4 | $1.15M | Buy |
34,336
+18,547
| +117% | +$517K | ﹤0.01% | 4965 |
|
|
2021
Q3 | $406K | Buy |
15,789
+7,028
| +80% | +$126K | ﹤0.01% | 5622 |
|
|
2021
Q2 | $117K | Sell |
8,761
-715
| -8% | -$8.84K | ﹤0.01% | 6285 |
|
|
2021
Q1 | $101K | Buy |
9,476
+1,000
| +12% | +$11.4K | ﹤0.01% | 6007 |
|
|
2020
Q4 | $68K | Sell |
8,476
-2,238
| -21% | -$17.6K | ﹤0.01% | 6058 |
|
|
2020
Q3 | $80K | Buy |
10,714
+3,012
| +39% | +$26.7K | ﹤0.01% | 5529 |
|
|
2020
Q2 | $69K | Buy |
7,702
+3,160
| +70% | +$32.8K | ﹤0.01% | 5558 |
|
|
2020
Q1 | $44K | Buy |
4,542
+989
| +28% | +$11.8K | ﹤0.01% | 5518 |
|
|
2019
Q4 | $51K | Buy |
3,553
+676
| +23% | +$9.86K | ﹤0.01% | 5852 |
|
|
2019
Q3 | $43K | Sell |
2,877
-19,537
| -87% | -$272K | ﹤0.01% | 5790 |
|
|
2019
Q2 | $297K | Buy |
22,414
+20,377
| +1,000% | +$247K | ﹤0.01% | 4850 |
|
|
2019
Q1 | $26K | Buy |
2,037
+606
| +42% | +$8.83K | ﹤0.01% | 5929 |
|
|
2018
Q4 | $21K | Sell |
1,431
-862
| -38% | -$14.1K | ﹤0.01% | 6004 |
|
|
2018
Q3 | $41K | Buy |
2,293
+1,803
| +368% | +$31.2K | ﹤0.01% | 5929 |
|
|
2018
Q2 | $7K | Buy |
490
+130
| +36% | +$2.29K | ﹤0.01% | 6379 |
|
|
2018
Q1 | $7K | Sell |
360
-3,178
| -90% | -$68.7K | ﹤0.01% | 6347 |
|
|
2017
Q4 | $81K | Buy |
3,538
+639
| +22% | +$20.5K | ﹤0.01% | 5703 |
|
|
2017
Q3 | $107K | Buy |
+2,899
| New | +$108K | ﹤0.01% | 5557 |
|
Morgan Stanley's OPNT Position: Q1 2023 in Review
Morgan Stanley sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 197,652 shares — an estimated $4.01M sold.
Morgan Stanley first reported a position in OPNT in Q3 2017 and held it in 22 quarters. The position peaked at $4.01M in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.
- Morgan Stanley reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Morgan Stanley sold 197,652 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $4.01M.
- Morgan Stanley first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 22 quarters.
- Morgan Stanley's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $4.01M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.